Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone

Xiao-Feng Li, Hao-Long Dong, Hong-Jiang Wang, Xing-Yao Huang, Ye-Feng Qiu, Xue Ji, Qing Ye, Chunfeng Li, Yang Liu, Yong-Qiang Deng, Tao Jiang, Gong Cheng, Fu-Chun Zhang, Andrew D. Davidson, Ya-Jun Song, Pei-Yong Shi and Cheng-Feng Qin ()
Additional contact information
Xiao-Feng Li: Beijing Institute of Microbiology and Epidemiology
Hao-Long Dong: Beijing Institute of Microbiology and Epidemiology
Hong-Jiang Wang: Beijing Institute of Microbiology and Epidemiology
Xing-Yao Huang: Beijing Institute of Microbiology and Epidemiology
Ye-Feng Qiu: Academy of Military Medical Science
Xue Ji: Beijing Institute of Microbiology and Epidemiology
Qing Ye: Beijing Institute of Microbiology and Epidemiology
Chunfeng Li: Beijing Institute of Microbiology and Epidemiology
Yang Liu: Tsinghua University
Yong-Qiang Deng: Beijing Institute of Microbiology and Epidemiology
Tao Jiang: Beijing Institute of Microbiology and Epidemiology
Gong Cheng: Tsinghua University
Fu-Chun Zhang: Guangzhou Medical University
Andrew D. Davidson: University of Bristol
Ya-Jun Song: Beijing Institute of Microbiology and Epidemiology
Pei-Yong Shi: University of Texas Medical Branch
Cheng-Feng Qin: Beijing Institute of Microbiology and Epidemiology

Nature Communications, 2018, vol. 9, issue 1, 1-11

Abstract: Abstract The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-02975-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-02975-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-02975-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().